Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Servier
Biotech
OSE's ulcerative colitis prospect improves symptoms in phase 2
Around one year after the French drugmakers split up, OSE has reported midphase data on its anti-IL-7 antibody lusvertikimab in ulcerative colitis.
Nick Paul Taylor
Jul 24, 2024 8:23am
ASCO: Servier finds survival benefit in difficult brain cancer
Jun 5, 2023 8:55am
Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win
Mar 14, 2023 10:15am
Servier severs CAR-T collab with Allogene
Sep 22, 2022 10:23am
Pieris puts phase 2 cancer drug out on chopping block
Aug 4, 2022 4:15pm
Servier takes aim at US oncology market, adds R&D lab in Boston
Jul 21, 2022 10:26am
